Literature DB >> 20954965

Review of hepatitis B therapeutics.

Debika Bhattacharya1, Chloe L Thio.   

Abstract

Currently, there are 7 approved therapies for chronic hepatitis B virus (HBV) infection, an increase from just 3 agents 5 years ago. This review will focus on the pharmacology, potency, and adverse events associated with immunomodulatory agents and nucleos(t)ide analogues, with an emphasis on targets of therapy within the HBV life cycle. We will also offer guidelines for the use of available anti-HBV agents and review the emerging challenges in hepatitis B management, including HBV drug resistance, its management, and the potential role of combination therapy.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20954965      PMCID： PMC2977969          DOI： 10.1086/656624

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  49 in total

1.  Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.

Authors:  Y Benhamou; M Bochet; V Thibault; V Di Martino; E Caumes; F Bricaire; P Opolon; C Katlama; T Poynard
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

2.  The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial.

Authors:  E J Fisher; K Chaloner; D L Cohn; L B Grant; B Alston; C L Brosgart; B Schmetter; W M El-Sadr; J Sampson
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

3.  Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.

Authors:  Vincent Di Martino; Thierry Thevenot; Jean-François Colin; Nathalie Boyer; Michèle Martinot; Françoise Degos; Jean-Pierre Coulaud; Jean-Louis Vilde; François Vachon; Claude Degott; Dominique Valla; Patrick Marcellin
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

4.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Authors:  Patrick Marcellin; Ting-Tsung Chang; Seng Gee Lim; Myron J Tong; William Sievert; Mitchell L Shiffman; Lennox Jeffers; Zachary Goodman; Michael S Wulfsohn; Shelly Xiong; John Fry; Carol L Brosgart
Journal:  N Engl J Med       Date:  2003-02-27       Impact factor: 91.245

5.  Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.

Authors:  S Levine; D Hernandez; G Yamanaka; S Zhang; R Rose; S Weinheimer; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

6.  Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Authors:  D J Tenney; S M Levine; R E Rose; A W Walsh; S P Weinheimer; L Discotto; M Plym; K Pokornowski; C F Yu; P Angus; A Ayres; A Bartholomeusz; W Sievert; G Thompson; N Warner; S Locarnini; R J Colonno
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

Authors:  Daniel J Tenney; Ronald E Rose; Carl J Baldick; Kevin A Pokornowski; Betsy J Eggers; Jie Fang; Michael J Wichroski; Dong Xu; Joanna Yang; Richard B Wilber; Richard J Colonno
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

8.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

Authors:  Anna S F Lok; Ching-Lung Lai; Nancy Leung; Guang-Bi Yao; Zhen-Yu Cui; Eugene R Schiff; Jules L Dienstag; E Jenny Heathcote; Nancy R Little; Dorothea A Griffiths; Stephen D Gardner; Mary Castiglia
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

9.  Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Authors:  W G E Cooksley; T Piratvisuth; S-D Lee; V Mahachai; Y-C Chao; T Tanwandee; A Chutaputti; W Yu Chang; F E Zahm; N Pluck
Journal:  J Viral Hepat       Date:  2003-07       Impact factor: 3.728

10.  Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.

Authors:  Gregory J Dore; David A Cooper; Anton L Pozniak; Edwin DeJesus; Lijie Zhong; Michael D Miller; Biao Lu; Andrew K Cheng
Journal:  J Infect Dis       Date:  2004-03-12       Impact factor: 5.226
View more
  28 in total

1.  Comparison of three Roche hepatitis B virus viral load assay formats.

Authors:  Michael T Pyne; Lauren Vest; Jennifer Clement; Jessica Lee; Jessica R Rosvall; Kevin Luk; Michael Rossi; Bryan Cobb; David R Hillyard
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

Review 2.  Antiviral therapies: focus on hepatitis B reverse transcriptase.

Authors:  Eleftherios Michailidis; Karen A Kirby; Atsuko Hachiya; Wangdon Yoo; Sun Pyo Hong; Soo-Ok Kim; William R Folk; Stefan G Sarafianos
Journal:  Int J Biochem Cell Biol       Date:  2012-04-16       Impact factor: 5.085

3.  MHC-E-Restricted CD8+ T Cells Target Hepatitis B Virus-Infected Human Hepatocytes.

Authors:  Benjamin J Burwitz; Patrick K Hashiguchi; Mandana Mansouri; Christine Meyer; Roxanne M Gilbride; Sreya Biswas; Jennie L Womack; Jason S Reed; Helen L Wu; Michael K Axthelm; Scott G Hansen; Louis J Picker; Klaus Früh; Jonah B Sacha
Journal:  J Immunol       Date:  2020-03-11       Impact factor: 5.422

4.  Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection.

Authors:  D D Byrne; C W Newcomb; D M Carbonari; M S Nezamzadeh; K B F Leidl; M Herlim; Y X Yang; S Hennessy; J R Kostman; M B Leonard; A R Localio; V Lo Re
Journal:  J Viral Hepat       Date:  2015-03-06       Impact factor: 3.728

5.  Large-scale production and structural and biophysical characterizations of the human hepatitis B virus polymerase.

Authors:  Judit Vörös; Annika Urbanek; Gilles Jean Philippe Rautureau; Maggie O'Connor; Henry C Fisher; Alison E Ashcroft; Neil Ferguson
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

6.  Inhibition of HBV replication by VPS4B and its dominant negative mutant VPS4B-K180Q in vivo.

Authors:  Jianbo Xia; Weipeng Wang; Lei Li; Zhi Liu; Min Liu; Dongliang Yang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-06-09

Review 7.  Clinical impact of hepatitis B and C virus envelope glycoproteins.

Authors:  Hélène Jeulin; Aurélie Velay; John Murray; Evelyne Schvoerer
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

8.  Seroprevalence of Hepatitis B and C Viruses Among Children in Kilimanjaro Region, Tanzania.

Authors:  Florida J Muro; Suzanne P Fiorillo; Philoteus Sakasaka; Christopher Odhiambo; Elizabeth A Reddy; Coleen K Cunningham; Ann M Buchanan
Journal:  J Pediatric Infect Dis Soc       Date:  2013-04-12       Impact factor: 3.164

9.  Establishment and application of hepatitis B virus persistent replication model in IFNAR(-/-) mouse.

Authors:  Ming-Fa Chen; Yong Lin; You-Chen Xia; Chan Sun; Xue-Mei Feng; Meng-Ji Lu; Dong-Liang Yang; Jun Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-06-17

10.  Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.

Authors:  J S Hafkin; M K Osborn; A R Localio; V K Amorosa; J R Kostman; J J Stern; P De La Torre; K Mounzer; I Frank; R Gross; K-M Chang; V Lo Re
Journal:  J Viral Hepat       Date:  2013-07-30       Impact factor: 3.728
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.